FasT
Beyond's analysis on FasT
- — IASO Bio's first-in-human Phase 1 data for the dual-targeted BCMA/GPRC5D CAR-T RD140 could redefine treatment for high-risk multiple myeloma, building on a pipeline that already includes FDA-cleared in vivo CAR-T assets
- — Triple B Media expands FAST channel ecosystem through partnership with Silver Sports & Entertainment for live NHL content
- — FAST funds Frances Arnold’s directed‑evolution platform to create RNA‑targeted nucleoside analogs for Angelman syndrome therapy
Recent news mentioning FasT
- — 2026 IMS | IASO Bio Presents First-in-Human Phase 1 Data of RD140, a Fully Human BCMA/GPRC5D Dual-Targeted FasT CAR-T
- — Nexpart Multi-Seller Helps Dealerships Get Used Vehicles Frontline-Ready Faster
- — In Deutschland: VW und Audi rufen fast eine Million Fahrzeuge zurück
- — Fastsættelse af kuponrente
- — Fastsættelse af kuponrente gældende fra 1. oktober 2026
- — Fastsættelse af rentekuponer for variabelt forrentede obligationer (EUR)
- — The fastest-growing spacetech startup teams in Europe
- — Waymo is scaling fast. Here’s what the fleet data shows.
- — Blinds To Go Selects Fastlane to Advance Brand Strategy and Integrated Campaign Marketing
- — Genossenschaftsbanken: Volksbank Brawo wickelt Gesellschaften der Sparte Green Energy ab – fast 60 Mitarbeiter sind betroffen
- — Assurity launches streamlined new Quick Issue Critical Illness Insurance for fast supplemental health sales
- — Hyperion DeFi Supports DoubleZero Edge in Launching the Fastest Commercially Available Hyperliquid Data Feeds